Piramal and Lilly Enter Major Drug Development Deal

Eli Lilly and Nicholas Piramal India Ltd. (NPIL; Mumbai), one of India’s biggest manufacturers of pharmaceuticals, have signed a major agreement to develop and market some of Lilly’s preclinical drug candidates covering a wide range of therapeutic areas. The agreement sets a new pattern in alliances for drug discovery and development, experts say. NPIL will be responsible for design and execution of the program, and the resulting developmental drugs will be registered with U.S. FDA as Investigational New Drug Applications (IND). Lilly and NPIL will...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers